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Ablepharon macrostomia syndrome (AMS) and Barber-Say syndrome (BSS) are rare congenital ectodermal dysplasias characterized by
similar clinical features. To establish the genetic basis of AMS and BSS, we performed extensive clinical phenotyping, whole exome and
candidate gene sequencing, and functional validations. We identified a recurrent de novo mutation in TWIST2 in seven independent
AMS-affected families, as well as another recurrent de novomutation affecting the same amino acid in ten independent BSS-affected fam-
ilies. Moreover, a genotype-phenotype correlation was observed, because the two syndromes differed based solely upon the nature of the
substituting amino acid: a lysine at TWIST2 residue 75 resulted in AMS, whereas a glutamine or alanine yielded BSS. TWIST2 encodes a
basichelix-loop-helix transcription factor that regulates thedevelopmentofmesenchymal tissues.All identifiedmutations fell in thebasic
domain of TWIST2 and altered the DNA-binding pattern of Flag-TWIST2 in HeLa cells. Comparison of wild-type and mutant TWIST2
expressed in zebrafish identified abnormal developmental phenotypes and widespread transcriptome changes. Our results suggest that
autosomal-dominant TWIST2mutations cause AMS or BSS by inducing protean effects on the transcription factor’s DNA binding.Introduction
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Table 1. Clinical Features of Individuals Harboring TWIST2 Mutations
Subject
TWIST2
Alteration Gender Eyelids Mouth Nose Ears Skin Hair Nipples Genitalia Hands Other Development
AMS-1.120 p.Glu75Lys M severe
hypoplastic
eyelids
bilateral
macrostomia depressed
nasal
bridge
microtia first
degree, cryptotia,
low-set
wrinkled sparse normal ambiguous normal hypertelorism normal
AMS-2.19 p.Glu75Lys
mosaic
M right upper
eyelid defect,
absent
eyelashes
normal normal microtia first
degree, increased
posterior
angulation
normal sparse normal normal normal – normal
AMS-2.29 p.Glu75Lys
paternally
inherited
F ablepharon
bilateral
macrostomia depressed
nasal bridge,
under-
developed
ala ansi
microtia first
degree, low-set
redundant sparse, absent
lanugo
hypoplastic hypoplastic
labia majora
cutaneous
syndactyly
hypertelorism –
AMS-2.39 p.Glu75Lys
paternally
inherited
F ablepharon
bilateral
macrostomia depressed
nasal bridge,
anteverted
nostrils
microtia first
degree
thin,
redundant
sparse, absent
lanugo
absent hypoplastic
labia majora
small nails omphalocele,
anteriorly
placed anus
–
AMS-3.1
(case 2 in
Stevens and
Sargent24)
p.Glu75Lys
de novo
M ablepharon
bilateral
macrostomia depressed
nasal bridge,
cleft ala nasi
microtia first
degree, low-set
thin, wrinkled sparse, absent
lanugo
hypoplastic ambiguous
genitalia,
micropenis,
cryptorchidsim
cutaneous
syndactyly,
camptodactyly
single
umbilical artery,
lipoma overlying
metopic suture
mild gross
and fine
motor
delay,
articulation
errors
with speech
AMS-4.1
(case 3 in
Stevens and
Sargent24)
p.Glu75Lys
de novo
F ablepharon
bilateral
macrostomia depressed
nasal bridge,
cleft ala nasi
microtia first
degree, low-set,
unilateral
hearing loss
thin, wrinkled sparse, absent
lanugo
normal hypoplastic
labia majora,
urethral
opening in
vagina
camptodactyly hemiparesis due
to cerebral
hemorrhage,
anteriorly
placed anus
mild
delays, receives
PT, OT, and
speech therapy
AMS-5.1
(case 4 in
Stevens and
Sargent24)
p.Glu75Lys
de novo
F ablepharon
bilateral
macrostomia cleft ali nasi microtia first
degree, mild
hearing loss
thin, wrinkled sparse, absent
lanugo
hypoplastic normal camptodactyly zygomatic
hypoplasia
normal
AMS-6.15 p.Glu75Lys
mosaic
F severe
hypoplastic
eyelids
bilateral,
absent
eyelashes
macrostomia under-
developed
ala nasi
microtia first
degree, high-
frequency
hearing loss
thin, wrinkled sparse hypoplastic
nipples
and breast
normal cutaneous
syndactyly,
camptodactyly
aplastic
zygomatic arches
normal
AMS-7.122 p.Glu75Lys
mosaic
M severe
hypoplastic
eyelids
bilateral
macrostomia? normal microtia first
degree
redundant variable
follicle
density on
posterior
scalp
normal ambiguous
genitalia
clinodactyly
radial f5
bilateral
low anterior
hairline,
omphalocele
normal
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Table 1. Continued
Subject
TWIST2
Alteration Gender Eyelids Mouth Nose Ears Skin Hair Nipples Genitalia Hands Other Development
AMS-7.222 p.Glu75Lys
paternally
inherited
M ablepharon
bilateral
macrostomia under-
developed
ala nasi
microtia first
degree
thin, redundant sparse, absent
lanugo
normal hypoplasia of
labia majora
cutaneous
syndactyly
omphalocele,
anteriorly
placed anus,
absent
zygomatic
arches
mild gross motor
delay, mild
receptive language
delay, significant
early expressive
language delay
BSS-1.110 Gln77_
Arg78dup
de novo
F severe
hypoplastic
eyelids
bilateral,
ectropion
macrostomia bulbous
nose
cup-shaped,
hypoplastic
external
auditory canals,
hearing loss
wrinkled, dry marked
hypertrichosis
inverted ‘‘snout-shaped’’
labia majora
normal velopharyngeal
incompetence
delayed
language
development,
dyslalia,
dysgrammatism
BSS-2.114 p.Glu75Gln
de novo
F ectropion macrostomia broad nasal
width,
bulbous
nose,
hypoplastic
ala nasi
microtia first
degree,
hypoplastic
external
auditory canals
wrinkled,
translucent
marked
hypertrichosis
normal ambiguous normal parental
consanguinity
–
BSS-3.1
(this
paper)
p.Glu75Gln
de novo
F ectropion macrostomia broad nasal
width,
bulbous and
prominent
nose
small,
hypoplastic
external
auditory canals
wrinkled,
visible veins
over thorax
marked
hypertrichosis
hypoplastic normal normal low anterior
hairline, sparse
eyebrows,
hypertelorism,
hypoplastic
maxilla, gum
hypertrophy,
widely spaced
teeth
mild delay
BSS-4.121 p.Glu75Gln
mosaic
M coarse
eyebrows,
telecanthus
macrostomia bulbous
nose, broad
nasal width
normal redundant,
dry skin
marked
hypertrichosis
inverted,
hypoplastic
normal normal low anterior
hair line
normal
BSS-4.221 p.Glu75Gln
paternally
inherited
F ectropion,
telecanthus,
epiblepharon
macrostomia,
mild
micrognathia
bulbous
nose, broad
nasal width
low-set ears, small
external canal,
concha, extra fold
redundant,
dry skin,
lipodystrophy
marked
hypertrichosis
inverted,
hypoplastic
normal normal low anterior
hair line, thin
vermillion
of lips
normal
BSS-4.321 p.Glu75Gln
paternally
inherited
F ectropion,
ocular
telecanthus,
epiblepharon
macrostomia,
mild
micrognathia
bulbous
nose, broad
nasal width
low-set ears,
microtia
first degree,
concha extra fold
redundant,
dry skin,
lipodystrophy
marked
hypertrichosis
inverted,
hypoplastic
normal normal low anterior
hair line, thin
vermillion
of lips
normal
BSS-5.125 p.Glu75Gln M ectropion
bilateral,
sparse lashes
macrostomia bulbous
nose
microtia first
degree
lax, redundant
skin
marked
hypertrichosis
hypoplastic shawl
scrotum
normal clubfeet,
reduced elastic
fibers on
skin biopsy
–
BSS-6.1
(this
paper)
p.Glu75Ala
de novo
F hypoplasia,
microblepharon,
ectropion
(bilateral)
macrostomia broad nasal
width,
bulbous
nose,
hypoplastic
ala nasi
microtia first
degree
thin (general),
redundant
(trunk)
marked
hypertrichosis
(back and
limbs)
hypoplastic mild
hypoplasia
of labia majora
brachydacytly
and clinodactyly
f5 prominent
digit pads
high palate,
lumbar flat
angioma
normal
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102 The American Journal of Human Genetics 97, 99–110, July 2, 201ectropion, macrostomia, ear abnormalities, bulbous nose
with hypoplastic alae nasi, redundant skin, hypertrichosis,
and variable other features.14,16,21,23,25,26 Several instances
of parent-to-child transmission suggest that both AMS
and BSS are inherited in an autosomal-dominant
fashion,2,8,9,21,22 but no specific gene defect has been asso-
ciated with these disorders. The substantial phenotypic
overlap between AMS and BSS, as well as a shared mode
of inheritance, supports the hypothesis that the two
disorders are caused by dominant mutations in the same
gene.10,15,16
We employed extensive clinical phenotyping, exome
sequencing, and expression studies to determine the
genetic basis for AMS and BSS. We show that both AMS
and BSS are due to dominant mutations in TWIST2 (MIM:
607556), affecting a highly conserved residue. TWIST2
(also called Dermo-1), which binds to E-box DNA motifs
(50-CANNTG-30) as a heterodimer with other bHLHproteins
such as the ubiquitously expressed protein E12, is thought
to act as a negative regulator of transcription.35–40 TWIST2
expression is temporally restricted and tissue specific. Dur-
ing embryonic development, TWIST2 is highly expressed
in the craniofacial mesenchyme and in chondrogenic
precursors. Previous studies suggest that TWIST2 regulates
mesenchymal stem cell differentiation and directs the
development of dermal and chondrogenic tissues.35,38,40,41
Disturbance of these processes due to dominant mutations
in TWIST2 could, therefore, cause the distinctive clinical
features and facial patterning defects observed in AMS
and BSS. Molecular analyses suggest that these mutations
alter the DNA-binding activity of TWIST2, leading to both
dominant-negative and gain-of-function effects.Methods
Individuals Included in the Study
The original six family members of a pedigree including AMS-7.1
and AMS-7.2 were enrolled in the NIH Undiagnosed Diseases
Program and admitted to the National Institutes of Health Clinical
Center (NIH-CC). That family, together with AMS-6.1, were
enrolled in protocol 76-HG-0238, ‘‘Diagnosis and Treatment of
Patients with Inborn Errors of Metabolism or Other Genetic Disor-
ders,’’ approved by the National Human Genome Research Insti-
tute (NHGRI) Institutional Review Board (IRB). Targeted genetic
testing, karyotype analysis, and chromosomal microarray analysis
revealed no significant findings. SNP array analysis showed no
anomalous regions of homozygosity or significant copy-number
variants. Studies of 7 additional AMS-affected individuals from
5 families and 12 BBS-affected individuals from 10 families were
approved by the institutional review boards of the Policlinico Tor
Vergata University Hospital, the University of Magdeburg, Univer-
sity Medical Center Utrecht, Ghent University Hospital, and
Radboud University Medical Center Nijmegen. Written informed
consent was obtained from all affected individuals or parents.
Electron Microscopy
Skin biopsies were fixed for 48 hr at 4C in 2% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.4) and washed with cacodylate5
buffer three times. The tissues were fixed with 2% OsO4 for 2 hr,
washed again with 0.1 M cacodylate buffer three times, washed
with water, and placed in 1% uranyl acetate for 1 hr. The tissues
were subsequently serially dehydrated in ethanol and embedded
in Spurr’s (Electron Microscopy Sciences). Semi-thick (~1,000 nm)
and thin (~80 nm) sections were obtained by utilizing the Leica
ultracut-UCT ultramicrotome (Leica) and placed either on glass
slides for toluidine blue staining or onto 300 mesh copper
grids and stained with saturated uranyl acetate in 50% methanol
and then with lead citrate. The grids were viewed in the JEM-
1200EXII electron microscope (JEOL Ltd) at 80 kV and images
were recorded on the XR611M, mid mounted, 10.5 Mpixel, CCD
camera (Advanced Microscopy Techniques).
Fibroblast Culture
Primary dermal fibroblasts were cultured from forearm skin-
punch biopsies as described.42 Genomic DNA was extracted from
AMS-3.1, -6.1, -7.1 (hyperpigmented, affected), and -7.2 and
from BSS-4.2 and -6.1 dermal fibroblasts as well as ATCC adult
control, AMS-7.1 (hypopigmented, unaffected), and the mother
of AMS-7.2 dermal fibroblasts as unaffected control.
Genetic Analysis
Genomic DNA was extracted from whole blood of AMS-7.1 and
AMS-7.2 and their unaffected familymembers via the Gentra Pure-
gene Blood Kit (QIAGEN). SNP analyses were performed with an
Illumina Omni Express 12 (hg18) SNP array and the Genome
Studio software program. Whole-exome sequencing was per-
formed with the Illumina HiSeq2000 platform and the TrueSeq
capture kit (Illumina) by the NIH Intramural Sequencing Center
(NISC). Sequence data were aligned to the human reference
genome (hg19) via Novoalign (Novocraft Technologies). Variants
were filtered based on allele frequencies in the NIH Undiagnosed
Diseases Program43–45 cohort (<0.06) and were confirmed by
Sanger sequencing.
Protein Modeling
A computerizedmodel of TWIST2 bound to DNAwas generated by
YASARa and WHAT IF Twinset via standard parameters with PDB:
1NKP (Myc-Max Recognizing DNA) as template. A homodimeric
model was produced by superimposing two TWIST2 models on
the original PDB: 1NKP file.
ChIP-Seq
Stably transfected T-REx-HeLa cells, treated for 24 hr with 1 mg/ml
tetracycline to induce recombinant WT, p.Glu75Lys, p.Glu75Gln,
p.Glu75Ala, and p.Gln77_Arg78dup TWIST2 overexpression,
were fixed, pelleted, and frozen according to a cell fixation proto-
col provided by Active Motif. Sheared chromatin from T-REx HeLa
cells without recombinant TWIST2 served as a negative control
and was similarly fixed, pelleted, and frozen as a negative control.
Chromatin shearing, ChIP, and DNA sequencing were performed
by Active Motif. ChIP was performed with a monoclonal anti-
FLAG M2 antibody (Sigma Aldrich). ChIPed DNA was sequenced
on the Illumina NextSeq 500 platform. Short reads were aligned
to human reference genome (hg19) with BWA.46 Binding peaks
were identified with MACS using standard parameters.47 Peaks
shared between different samples as well as the Jaccard coefficients
representing the correlations between samples were calculated
with BedTools.48 Peaks were annotated and summarized with
CEAS.49 The consensus-binding motif for the WT TWIST2 sampleThe Apeaks was determined with GEM2.5 with a minimum k-mer
length of 6 and a maximum k-mer length of 20.50Plasmids and Transfection
pCMV6 plasmid containing human TWIST2 cDNAwas purchased
from Origene Technologies. TWIST2 cDNA was amplified by PCR
with Platinum Taq DNA Polymerase High Fidelity (Life Technolo-
gies) using pCMV6/TWIST2 plasmid as template. PCR amplifica-
tion was performed with a forward primer containing FLAG-HA
tags. The PCR product was then cloned into the Gateway entry
vector pENTR/D-TOPO (Life Technologies) according to the man-
ufacturer’s protocol. Mutations associated with AMS and BSS
(c.223G>A [p.Glu75Lys], c.223G>C [p.Glu75Gln], c.224A>C
[p.Glu75Ala], and c.229_234dupCAGCGC [p.Gln77_Arg78dup])
were introduced into the TWIST2 containing pENTR/D-TOPO
plasmid with the QuikChange Lightning Site-Directed Mutagen-
esis kit (Agilent) according to manufacturer’s protocol. All primer
sequences are listed in Table S1. TWIST2 inserts were then recom-
bined into the Gateway mammalian expression plasmid pT-REx-
DEST30 (Life Technologies) according to the manufacturer’s
protocol.
T-REx-HeLa cells (Life Technologies) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10% (v/v) heat-
inactivated fetal bovine serum, 1% (v/v) penicillin-streptomycin,
and 5 mg/ml blasticidin. T-REx-HeLa cells were transfected with
2.5 mg pT-REx-DEST30 vector with Lipofectamine 2000 reagent
(Life Technologies) and selected with 400 mg/ml Geneticin. Indi-
vidual clones were screened for TWIST2 expression before and
after 24 hr treatment with 1 mg/ml tetracycline. Clones with the
highest expression after 24 hr and with minimal leaky expression
were chosen for use in further assays.Zebrafish Experiments
Zebrafish (Danio rerio) were maintained under an approved animal
study protocol, in accordance with the Zebrafish Book.51 The hu-
man wild-type andmutant TWIST2 (p.Glu75Lys and p.Glu75Gln)
were cloned into pCS2GW by Gateway (Life Technologies).
Subcloned cDNAs were linearized and used for in vitro synthesis
of capped mRNA via mMESSAGE mMACHINE SP6 Ultra Kit
(Life Technologies). Wild-type embryos of Tupfel long fin (TL)
strain embryos were injected at the one-cell stage with 10 pg
(phenotypical analysis) or 2 pg (RNA sequencing)mRNA. Embryos
were raised at 28C in Embryo Medium (E3).
For RNA sequencing, total RNA was extracted from approxi-
mately 70 non-injected, wild-type hTWIST2 mRNA-injected,
p.Glu75Lys mRNA-injected, and p.Glu75Gln mRNA-injected
zebrafish embryos at shield stage in triplicate. Each embryo was
microinjected with approximately 10 pg mRNA. RNA extraction
was carried out with TRizol (Life Technologies BV) according to
the manufacturer’s recommendations. For all samples, total RNA
was re-suspended in MQ water prior to sequencing. RNA-seq
libraries were prepared according the TruSeq Stranded Total RNA
Sample Preparation, Low Sample (LS) protocol. The 12 RNA-seq
samples were run on a single HiSeq2500 flow cell. Quality control
in FastQ files was performed with FastQC, followed by alignment
to the zebrafish genome via STAR.52 A second-quality control
step was performed on the generated BAM files via Picards
collectRNAMetrics. The read count per gene was determined by
HTSeq-count and normalized with DESeq.53 Differential expres-
sion analysis was done on the normalized read count tables.
GO term analysis was carried out with Gorilla in fast mode54,55merican Journal of Human Genetics 97, 99–110, July 2, 2015 103
Figure 1. Clinical, Histological, and
Molecular Defects in Ablepharon-Macro-
stomia Syndrome and Barber-Say Syn-
drome
(A) Face, shoulders, and hands of AMS-6.1,
AMS-7.1, and AMS-7.2, demonstrating
dysmorphic features detailed in Table 1.
Shoulder photographs of AMS-6.1 and
AMS-7.1 highlight Blaschko-like hyperpig-
mented banding indicative of mosaicism.
Hands show mild cutaneous syndactyly
and clinodactyly.
(B) Electron microscopy of skin of unaf-
fected control (1), AMS-6.1 (2), AMS-7.1
(3), and AMS-7.2. In (1), the elastin
(asterisk) is ovoid in shape, whereas in (2),
(3), and (4), the elastin appears elongated
and, in some areas, fractured. Collagen
fibers in (1) appear organized and are ori-
ented in bundles. In (3) and (4), some
collagen fibers appear in disarray (arrows)
and show curved edges. In addition, some
collagen fibers show variable diameters
(6). Surrounding the elastin in (5) (AMS-
7.1) and (6) (AMS-7.2) are flocculent and
amorphous deposits that disrupt organiza-
tion of collagen bundles. Scale bars repre-
sent 1,000 nm (1–4) and 500 nm (5 and 6).
(C) Face, back, and hands of BSS-3.1 and
BSS-4.2 showing dysmorphic features
detailed in Table 1. Note hypertrichosis.
(D) Electron microscopy of skin of BSS-3.1.
Note the long and thin elastin fibers
(asterisk) and collagen fibers in disarray
(arrow) in (1). Similar to AMS, some
collagen fibers show variable diameters (2). Surrounding the elastin in (3) are flocculent and amorphous deposits that disrupt organiza-
tion of elastin and collagen bundles. Scale bars represent 1,000 nm (1) and 500 nm (2 and 3).on the expression profiles of the top 10,000 protein-coding genes
ranked on adjusted p value from zebrafish embryos overexpressing
hTWIST2 variants. The analysis was carried out on datasets of
26,457 protein-coding genes for p.Glu75Lys and p.Glu75Gln after
comparison with wild-type hTWIST2-overexpressing samples.Results
Clinical Characteristics
The clinical features of the AMS-affected cohort were previ-
ously described in the literature, and their findings and the
original citations are listed in Table 1. Overall, the persons
with AMS exhibited ablepharon or microblepharon, mac-
rostomia, varying anomalies of the nose and ears, lax
redundant skin, sparse hair, variable abnormalities of the
nipples, genitalia, fingers, and hands, and largely normal
intellectual and motor development. AMS-6.1, AMS-7.1,
and AMS-7.2 have typical facial, extremity, and adipose
features typical of AMS (Figure 1A). Extensive craniofacial
phenotyping of AMS-7.2 also identified undescribed fea-
tures of harlequin-shaped eyebrows with absence of the
distal third, a hypoplastic nasal dorsumwith no projection
of the nasal tip, absent columella, hypoplastic ala nasi,
macrostomia, CL II malocclusion with 50% overbite, a
Brody bite, conical shaped teeth, and a long uvula. The
macrostomia was characterized by deficient lateral devel-104 The American Journal of Human Genetics 97, 99–110, July 2, 201opment of the vermillion border and an inability to raise
the oral commissures upon smiling, suggesting a disconti-
nuity of the orbicularis oris muscle. Electronmicroscopy of
skin biopsies of AMS-7.1 and AMS-7.2 showed thin, disrup-
ted elastic fibers with areas of amorphous deposits along
abnormally oriented collagen fibers and adjacent areas of
microfibrillar proliferation (Figure 1B). Masson-Trichrome
staining showed abnormal reticulodermal collagen pat-
terns in AMS-7.1 and AMS-7.2 (Figure S1A), whereas elastic
fiber (Elastic Van Geison) staining appeared within normal
limits (Figure S1B).
The BSS-affected individuals exhibited ectropion,macro-
stomia, bulbous noses, malformed ears in the spectrum of
microtia first degree, thin, redundant skin, hypertrichosis,
hypoplastic nipples, and normal hands and development,
together with other variable features (Table 1; Figure 1C).
Electron microscopy of the skin biopsy of BSS-3.1 showed
findings similar to those of AMS, i.e., thin and long
elastic fibers, abnormally oriented collagen fibers, and areas
of microfibrillar proliferation and amorphous deposits
(Figure 1D). BSS-3.1 and BSS-9.1 have not been previously
reported; their clinical features are detailed in Table 1.
DNA Studies
Initial studies were performed on two individuals with
AMS (7.1 and 7.2), members of a three-generation5
Figure 2. Mutations in the Basic Domain
of TWIST2 Associated with AMS and BSS
(A) Schematic of TWIST2 (GenBank:
NP_476527.1) with locations of de novo
missense variants identified in individuals
with AMS and BSS.
(B) Protein sequence alignment of verte-
brate TWIST2 homologs. Residues in the
basic domain affected by de novo variants
are shaded gray.
(C) Dimeric TWIST2 bHLH protein (gray)
with boundDNA (yellow)model with inset.
The p.Glu75 residue (red) is oriented to-
ward the DNA major grove; this residue
could be involved in hydrogen bonding
with the first two nucleotides of the
consensus E-box motif or positioning resi-
due p.Arg78.pedigree. Targeted genetic testing, karyotype analysis, and
chromosomal microarray analysis revealed no significant
findings. SNP array analysis showed no anomalous regions
of homozygosity or significant copy-number variants.
Exome sequencing on all family members revealed a single
nonsynonymous heterozygous mutation in TWIST2,
c.223G>A (GenBank: NM_057179.2), encoding the pre-
dicted deleterious protein alteration p.Glu75Lys. Targeted
sequencing revealed the same TWIST2 mutation in
ten AMS-affected individuals from seven independent
families (Table 1). Targeted sequencing of 11 BSS-affected
individuals (Figure 1B) identified heterozygous missense
mutations; nine had a c.223G>C (p.Glu75Gln) mutation
(GenBank: NM_057179.2) and two had c.224A>C
(p.Glu75Ala) mutations (GenBank: NM_057179.2). A
12th individual with BSS, BSS-1.1, carried a heterozygous
c.229_234dupCAGCGC (p.Gln77_Arg78dup) mutation
(GenBank: NM_057179.2) in TWIST2 (Table 1).
In all instances in which DNA was available from both
unaffected parents, the TWIST2 mutation occurred de
novo in the first generation of individuals affected with
AMS or BSS and was heritable in the third generation.
Three disease-transmitting fathers with mild AMS or BSS
and variable skin pigmentation were mosaic for a TWIST2
mutation, based upon next-generation sequencing of
peripheral blood DNA (AMS-6.1) and Sanger sequencing
of DNA from affected and unaffected skin (AMS-7.1)
(Figure S2). None of the disease-causing TWIST2mutations
were present in the NIH Undiagnosed Diseases Program’s
exome cohort, and none were reported in public variantThe American Journal of Hudatabases such as NHGRI CLINSEQ,36
dbSNP 142,35 1000 Genomes Project
Database, NHLBI Exome Sequencing
Project EVS v.0.0.30, or the ExAC data-
base (see Web Resources).
Protein Modeling
TWIST2 contains three functional
domains: basic, helix-loop-helix, and
twist box (Figure 2A). The TWIST2alterations associated with AMS and BSS (p.Glu75Lys,
p.Glu75Gln, p.Glu75Ala, and p.Gln77_Arg78dup) all
fall within the basic domain of the protein, which
mediates DNA binding. The residues affected in AMS
and BSS are conserved from zebrafish to human (Fig-
ure 2B). In silico TWIST2 modeling suggests that muta-
tions affecting the p.Glu75 residue do not alter global
protein structure but could alter DNA binding (Figure 2C).
The p.Glu75 residue is putatively oriented toward the
major groove of bound DNA and in close proximity to
the first two nucleotides of the E-box motif. Therefore,
the mutations associated with AMS and BSS (as well as
p.Gln77_Arg78dup) could alter the DNA-binding activity
of TWIST2.
Wild-Type and Mutant TWIST2 Binding Sites
We characterized the binding pattern of both wild-type
and mutant TWIST2 in an agnostic and genome-wide
fashion. Specifically, we performed ChIP-seq on sheared
cross-linked chromatin from T-REx HeLa cells overexpress-
ing recombinant FLAG-HA-tagged TWIST2 proteins;
sheared chromatin from T-REx HeLa cells without recom-
binant TWIST2 served as a negative control. We identified
630 binding peaks associated with wild-type TWIST2.
Events associated with wild-type TWIST2 binding were
significantly enriched (p < 0.05) near promoters
(<1,000 bp, <2,000 bp, and <3,000 bp) as well as in 50
UTRs (data not shown). The consensus binding motif
determined for wild-type TWIST2 was 50-CATCTGG-30
(Figure 3A), which represents a canonical E-box. Theman Genetics 97, 99–110, July 2, 2015 105
Figure 3. Effect of TWIST2 Mutations on HeLa Cell DNA Binding Sites and on Zebrafish Development and Gene Expression
(A) Chromatin from HeLa cells overexpressing wild-type TWIST2 was subjected to ChIP-seq, identifying 630 DNA binding sites with a
consensus sequence typical of an E-box motif.
(B) ChIP-seq showed that the numbers of binding sites for p.Glu75Lys, p.Glu75Gln, p.Glu75Ala, and p.Gln77_Arg78dup TWIST2 were
reduced compared to WT TWIST2 and that the mutants bound to many sites not shared with WT TWIST2.
(C) Schematic of the zebrafish studies, involving embryos microinjected with mRNA at the 1-cell stage and either used at shield stage
(6 hpf) for RNA-seq or left to grow until approximately 30 hpf for phenotypic characterization.
(D) Appearance of mild, moderate, and severely affected embryos, and quantification of the phenotypes induced at 30 hpf by overex-
pression of WT, p.Glu75Lys, and p.Glu75Gln hTWIST2. Embryos were injected at the 1-cell stage with 10 pg mRNA. hTWIST2 variants
induced defects in head structures and failure of the posterior end of the embryo to extend properly. The p.Glu75Lys and p.Glu75Gln
mutants induced stronger developmental defects than wild-type hTWIST2 mRNA.
(E) GO term analysis on ranked gene lists from RNA-seq for p.Glu75Lys and p.Glu75Gln mRNA. Extracellular matrix, membrane, and
cytoskeleton proteins are downregulated.TWIST2 alterations (p.Glu75Lys, p.Glu75Gln, p.Glu75Ala,
and p.Gln77_Arg78dup) shared only a fraction of their
binding peaks with WT TWIST2 (Figure 3B); p.Glu75Ala
and p.Gln77_Arg78dup TWIST2, both associated with106 The American Journal of Human Genetics 97, 99–110, July 2, 201BSS, shared only 25 binding peaks in common with the
wild-type. A significant number of binding peaks detected
for the mutant TWIST2 proteins were not detected for the
wild-type protein (Figure 3B).5
TWIST2 and Zebrafish Development
To elucidate the effect of TWIST2 mutations in vivo,
we assessed the functional consequences of injecting
wild-type and mutant (p.Glu75Lys and p.Glu75Gln)
human TWIST2 (hTWIST2) mRNA into zebrafish at
the 1-cell stage (Figure 3C). The introduction of wild-
type hTWIST2 led to mild developmental defects
(mainly mild brain hypoplasia) in approximately 65%
of injected zebrafish (Figure 3D). The injection of
p.Glu75Lys and p.Glu75Gln hTWIST2 RNA, however,
led to predominantly intermediate and severe develop-
mental defects, including severe head hypoplasia,
unclear midbrain-hindbrain boundary, dysmorphic body
trunk, and pericardial edema. These results were con-
firmed in stable transgenic zebrafish lines that express
human wild-type and mutant TWIST2 (p.Glu75Lys and
p.Glu75Gln) under the control of a Cre-loxP inducible
system (Figure S3A).
To gain insight into the genetic processes underlying
the developmental phenotypes, we performed RNA
sequencing on injected embryos at shield stage. Compared
to injection of wild-type hTWIST2, injection of p.Glu75Lys
or p.Glu75Gln hTWIST2 caused differential expression of
162 genes from a total of 26,457 datasets (adjusted p value
< 0.05); of these, 28 were common to both p.Glu75Lys
and p.Glu75Gln hTWIST2 injection (Figure S3B) and all
but one were up- or downregulated in the same fashion
in both mutants (Figure S3C). The majority of expression
changes of these target genes induced by overexpression
of p.Glu75Lys and p.Glu75Gln were confirmed by
analyzing the stable transgenic zebrafish embryos (Fig-
ure S3D). Gene ontology (GO) analyses revealed the
greatest reduction in the expression of genes related to
extracellular matrix (ECM), membrane components, and
cytoskeleton (fibrils) (Figure 3E).Discussion
We have shown that recurrent dominant mutations in
the DNA binding domain of TWIST2 are responsible for
two ectodermal dysplasias associated with congenital
malformations and dysmorphic facial features, i.e., AMS
and BSS. All 10 AMS-affected and 11 of 12 BSS-affected
individuals carried a mutation in the highly conserved
p.Glu75 amino acid (either p.Glu75Lys, p.Glu75Gln, or
p.Glu75Ala). Mutations in the basic domain of TWIST2
drastically altered the spectrum of DNA binding, reducing
normal binding and increasing binding to off-target
sites. The dominant nature of the mutations, then, could
be explained by the abnormal 50% of TWIST2 homo-
dimers and bHLH heterodimers that either reduced
binding to the normal contingent of DNA binding
sites or conferred a neomorphic function by binding to
other sites. Based upon the multitude of DNA binding
sites affected by AMS and BSS mutations, the phenotypic
manifestations of both AMS and BSS probably resultThe Afrom transcriptional effects on more than a single gene.
Our findings support the importance of the DNA bind-
ing domain of bHLH transcription factors: autosomal-
dominant mutations in the DNA binding domain of
TWIST1 (GenBank: NM_000474.3; MIM: 601622), another
member of the bHLH transcriptional regulators, have
been associated with Saethre-Chotzen syndrome (MIM:
101400), which is characterized with craniosynostosis and
limb abnormalities.56,57
Development appears to be exquisitely sensitive to the
influence of TWIST2. Simple overexpression of the wild-
type protein in zebrafish caused a mild developmental
phenotype. In addition, although AMS and BSS result
from missense mutations of the same amino acid,
p.Glu75, the phenotypes depend on the substituting
amino acid. A lysine at TWIST2 residue 75 results in
AMS, whereas a glutamine or alanine yields BSS. This
suggests that a single amino acid alteration, yielding
two phenotypically distinct disorders, dictates specific
groups of targeted developmental genes, some shared
and some not shared between AMS and BSS (Figure S4B).
Those genes might well encode proteins of the extracel-
lular matrix, whose expression in zebrafish was downre-
gulated by the mutations that cause AMS and BSS
(Figure S3). In fact, the phenotypes of those zebrafish
are reminiscent of sly and bal mutants,58 which are loss-
of-function alleles of gamma-1- and alpha-1-laminins,
key components of the extracellular matrix. TWIST2 is
recognized as a key regulator of mesenchymal cell fate
during embryonic development and of epithelial-mesen-
chymal transition in human cancers;59–63 therefore,
TWIST2 mutations might alter the ECM by causing aber-
rant gene expression.
We conclude that recurrent dominant mutations in the
DNA binding domain of TWIST2 are responsible for AMS
and BSS, ectodermal dysplasias with congenital malforma-
tions and dysmorphic facial features. All 10 AMS-affected
and 11 of 12 BSS-affected individuals had an alteration
in p.Glu75 of TWIST2. The zebrafish developmental
anomalies arising from injection of mutant TWIST2
RNA and ChIP studies suggest two possible mechanisms:
a dominant-negative effect due to loss of binding to the
normal contingent of TWIST2 DNA binding sites or a
neomorphic mechanism due to binding of the mutant
TWIST2 to extraneous promoter sites. Supporting a
contribution by the first mechanism is the phenotypic
overlap with Setleis syndrome (MIM: 227260), a less
severe ectodermal dysplasia characterized by bitemporal
lesions as well as eyelash and eyebrow defects,64–68 that
has been associated with homozygous loss-of-function
mutations in TWIST2.Supplemental Data
Supplemental Data include three figures, one table, and Supple-
mental Methods and can be found with this article online at
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